Updated Story The incoming Trump administration is already facing suggestions from a fiscally conservative think tank to scrap CMS’ proposal to cover obesity drugs, for a potential $40 billion savings over 10 years, but Trump’s cost-cutting czar is suggesting the better option would be to bring down the drugs’ prices. GLP-1s have widely been expected to be part of the next round of Medicare price negotiations, and President-elect Donald Trump’s CMS faces a Feb. 1 deadline to...